Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor ( EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor ( EGFR-TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. After initiating osimertinib treatment, the patient began to complain of low-grade fever and shortness of breath without hypoxemia, and her chest radiograph and a CT scan revealed a remarkable antitumor response, although faint infiltrations were observed in the bilateral lung field. Bronchoalveolar lavage fluid mainly contained lymphocytes (CD4+/CD8+ ratio of 0.3), and a transbronchial lung biopsy specimen showed lymphocytic alveolitis with partial organization in several alveolar spaces. Therefore we diagnosed the patient with osimertinib-induced interstitial lung disease (ILD) after treatment with anti-PD1 antibody. We considered anti-PD1 therapies may be the risk factor of EGFR-TKI-induced ILD.

          Related collections

          Most cited references 3

          • Record: found
          • Abstract: not found
          • Article: not found

          136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.

           S-W Kim,  A Walding,  H Yu (2016)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Consensus statement for the diagnosis and treatment of drug-induced lung injuries.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

                Bookmark

                Author and article information

                Contributors
                +81-55-989-5230 , h.kenmotsu@scchr.jp
                Journal
                Invest New Drugs
                Invest New Drugs
                Investigational New Drugs
                Springer US (New York )
                0167-6997
                1573-0646
                6 September 2016
                6 September 2016
                2017
                : 35
                : 1
                : 105-107
                Affiliations
                [1 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Thoracic Oncology, , Shizuoka Cancer Center Hospital, ; 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777 Japan
                [2 ]ISNI 0000 0004 0377 8408, GRID grid.415466.4, Department of Pulmonary Medicine, , Seirei Hamamatsu General Hospital, ; Shizuoka, Japan
                [3 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Pathology, , Shizuoka Cancer Center Hospital, ; Shizuoka, Japan
                [4 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Diagnostic Radiology, , Shizuoka Cancer Center Hospital, ; Shizuoka, Japan
                Article
                389
                10.1007/s10637-016-0389-9
                5306260
                27599705
                © The Author(s) 2016

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                Categories
                Short Report
                Custom metadata
                © Springer Science+Business Media New York 2017

                Comments

                Comment on this article